Invetech Videos

  1. How To Develop And Maintain A Scalable Cell Therapy Manufacturing Process 7/3/2024

    In this segment, Will Junker and Nick Siciliano share their expertise on how venture capital, driving clinical trials, and clear path to commercialization all help to achieve scalability.

  2. The Importance of Advanced Analytics in Cell Therapy Manufacturing 7/3/2024

    In this segment, expert panelists explain the advanced analytics and process monitoring technologies utilized in cell therapy manufacturing and how they help improve process control and product quality.

  3. The Primary Benefits Of Closed-System Manufacturing 7/3/2024

    Experts explain the primary benefits of closed-system manufacturing for cell therapies, particularly in terms of product quality, safety, and regulatory compliance, during this Cell & Gene Live Event.

  4. The Future Of Automation & Robotics In Cell Therapy Manufacturing 7/3/2024

    Expert panelists on the Cell & Gene Live event discuss the tasks and processes currently automated in the cell & gene therapy space, as well as how automation technologies impact job roles and skill requirements.

  5. The Current State Of Cell Therapy Manufacturing 7/3/2024

    Expert panelists on Cell & Gene Live, Inside Next-Gen Platforms for Cell Therapy Manufacturing, share their points of view on cell therapy manufacturing as it stands today.

  6. Key Considerations For Automating A Cell Therapy Manufacturing Program 4/24/2024

    Delve into the dynamic transition towards automation in cell and gene therapy manufacturing as well as the challenges it presents to start ups with industry experts in this webinar.

  7. Elutriation And Washing In One System 6/21/2022

    This elutriation and wash system can be used to initiate a wide number of cell therapy manufacturing processes such as CAR-T, dendritic cells, TIL, and IPSC-derived therapy.

  8. Closing Ancillary Processes: The New Bottleneck In Cell and Gene Therapy 4/15/2021

    One of the continued challenges for scalable commercial manufacturing of cell therapies is closing and automating the entire manufacturing process. Many core manufacturing processes may be closed, but peripheral systems e.g. media formulation, viral vector packaging remain open – introducing opportunities for failures. Invetech’s approach enables manufacturers to close and integrate both core and peripheral processes.

  9. True Innovations In Driving Down Cell Therapy Manufacturing 2/26/2021

    In this webinar segment, Dr. Mark Gilbert, Thomas Lequertier, and Luděk Sojka talk through the innovations in the manufacturing processes for both autologous and allogeneic therapies.

  10. The Why Behind The Expense Of Cell Therapy Manufacturing 2/26/2021

    In this webinar segment, Dr. Mark Gilbert, Thomas Lequertier, and Luděk Sojka address the reasons why cell manufacturing has been expensive to date — from viral vector production to the quality testing of a single-lot product, and more.